Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Investigate Etokimab (ANB020) in Adult Subjects With Chronic Rhinosinusitis With Nasal Polyposis

NCT03614923 is registered in ClinicalTrials.gov with AnaptysBio, Inc. as lead sponsor.

NCT NCT03614923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03614923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Investigate Etokimab (ANB020) in Adult Subjects With Chronic Rhinosinusitis With Nasal Polyposis
Lead sponsor
AnaptysBio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2018
Completion date
October 26, 2020
Enrollment
105 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis